INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 1.3M | 200.0K | 1.8M | 2.2M |
| Cost of Revenue | 1.7M | 2.5M | 2.3M | 1.2M | 110.2M |
| Gross Profit | (1.7M) | (1.2M) | (2.1M) | 609.0K | (108.0M) |
| Operating Expenses | |||||
| R&D Expense | 102.5M | 113.0M | 203.7M | 190.6M | 110.2M |
| SG&A Expense | 24.8M | 23.3M | 127.9M | 29.4M | 21.1M |
| General & Admin Expense | 24.8M | 23.3M | 127.9M | 29.4M | 21.1M |
| Selling & Marketing Expense | (7.0K) | — | — | — | — |
| Other Expenses | (1.1M) | (2.5M) | (2.3M) | (199.0K) | (110.2M) |
| Total Operating Expenses | 126.1M | 133.8M | 329.4M | 219.8M | 21.1M |
| Cost and Expenses | 127.8M | 136.3M | 331.6M | 221.0M | 131.3M |
| Operating Income (EBIT) | (127.8M) | (135.0M) | (331.4M) | (219.2M) | (129.1M) |
| Non-Operating | |||||
| Interest Income | 5.4M | 7.5M | 10.9M | 11.9M | — |
| Interest Expense | 15.6M | 12.2M | 13.5M | 31.8M | 16.1M |
| Net Interest Income | (10.2M) | (4.6M) | (2.6M) | (19.9M) | (16.1M) |
| Other Non-Op Income/Expense | (10.4M) | (5.0M) | 2.0B | (20.5M) | (16.1M) |
| Non-Operating Income (excl Interest) | (5.2M) | (7.2M) | (2.0B) | (11.3M) | (2.1M) |
| EBT (Pre-Tax Income) | (138.2M) | (140.1M) | 1.7B | (239.7M) | (145.2M) |
| Income Tax Expense | 3.0K | 2.0K | 2.0K | 3.0K | 3.0K |
| Bottom Line | |||||
| Net Income | (138.2M) | (140.1M) | 1.7B | (241.4M) | (145.2M) |
| Earnings from Cont. Ops | (138.2M) | (140.1M) | 1.7B | (239.7M) | (145.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (138.2M) | (140.1M) | 1.7B | (241.4M) | (145.2M) |
| Per Share | |||||
| Basic EPS | ($8.88) | ($9.04) | $116.58 | ($5.12) | ($3.62) |
| Diluted EPS | ($8.88) | ($9.04) | $116.58 | ($5.12) | ($3.62) |
| Revenue Per Share | $0.00 | $0.08 | $0.01 | $0.04 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 15.7M | 15.5M | 14.5M | 47.1M | 40.1M |
| Diluted Shares Outstanding | 15.7M | 15.5M | 14.5M | 47.1M | 40.1M |
| Profitability Metrics | |||||
| EBITDA | (120.4M) | (125.4M) | 1.7B | (206.7M) | (125.8M) |
| D&A | 2.2M | 2.5M | 2.3M | 1.2M | 1.2M |
| EBIT | (122.7M) | (127.9M) | 1.7B | (207.9M) | (127.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026